( num family of compounds. Over the past ...)Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting,Health

num family of compounds. Over the past two decades, platinum- based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Unlike the platinum drugs currently on the market, all of which require intravenous administration, satraplatin is an oral compound and is given as capsules that patients can take at home.

In addition to HRPC, satraplatin has been studied in clinical trials involving a range of tumors. Trials evaluating the effects of satraplatin in combination with radiation therapy, in combination with other cancer therapies and in a number of cancer types are underway or planned.

In 2002, Spectrum licensed the global rights to GPC Biotech . GPC Biotech is responsible for all costs associated with the development and regulatory filings of satraplatin. GPC Biotech has a co-development and license agreement with Pharmion GmbH, a wholly owned subsidiary of Pharmion Corporation, under which Pharmion has been granted exclusive commercialization rights to satraplatin for Europe and certain other territories. Spectrum licensed worldwide rights to satraplatin from Johnson Matthey PLC.

Satraplatin is a novel platinum analog with good oral bioavailability. A New Drug Application (NDA) for its initial indication, advanced hormone refractory prostate cancer, has recently been accepted by the FDA and given priority review status, with a date of August 15, 2007 for a decision regarding the approval of the NDA.

About SPI-1620

SPI-1620 is an endothelin B agonist that stimulates receptors on endothelial cells, the innermost layer of cells lining the blood vessels, to selectively dilate blood vessels in the tumor, resulting in a transient increase in blood flow and a consequent increase in the delivery of anti- cancer drugs to the tumor, as shown in animal studies to date. Tumors get their blood supply from blood vessels that are different from normal blood vessels and lack the surr
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
2. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)